Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics develops clinical-stage cardiopulmonary therapies, with news centered on levosimendan and TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company describes itself as a Phase 3, development-stage pharmaceutical company and reports on the LEVEL and LEVEL-2 registrational programs, intellectual property, and global development rights for levosimendan.
Recurring announcements also cover financial results, corporate updates, investor conference participation, executive appointments, and equity-based inducement grants under Nasdaq rules. These updates connect Tenax's drug-development program with governance, finance, product-development, clinical operations, and commercial-preparation activities.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced its presentation and virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The pre-recorded presentation will be available on-demand starting March 9 at 7:00 A.M. (EST) on their website, tenaxthera.com. Tenax focuses on developing therapeutics for cardio-pulmonary diseases, with rights to levosimendan and plans for a pivotal trial of imatinib. Both drugs target significant unmet medical needs in their respective areas.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the appointment of four new board members: June Almenoff, MD, PhD, Michael Davidson, MD, Declan Doogan, MD, and Stuart Rich, MD. CEO Anthony DiTonno expressed enthusiasm for their expertise, which is seen as crucial for advancing the company’s two leading pipeline assets into late-stage clinical testing. These assets include a new formulation of imatinib for pulmonary arterial hypertension and an oral formulation of levosimendan, which has been in-licensed from Orion. The new board members bring extensive experience in biopharma and clinical development.
Tenax Therapeutics, Inc. (Nasdaq: TENX) is set to host an investor conference call on January 21, 2021, discussing its recent acquisition of PH Precision Med, focused on developing imatinib for pulmonary arterial hypertension. The company aims to advance a delayed-release oral formulation of imatinib into a pivotal trial via the 505(b)(2) pathway. Tenax specializes in products targeting cardiovascular and pulmonary diseases and has recently released Phase 2 clinical trial data for levosimendan in treating pulmonary hypertension associated with heart failure.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced its acquisition of PH Precision Med, a biotech firm developing imatinib for pulmonary arterial hypertension (PAH). Imatinib, now with Orphan Drug Designation from the FDA, is set to enhance Tenax's pipeline as a Phase 3 ready candidate. The company aims to advance a delayed-release oral formulation of imatinib to mitigate side effects. The acquisition includes stock issuances and appoints Dr. Stuart Rich as Chief Medical Officer, enhancing Tenax's expertise in pulmonary hypertension.
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported its Q3 2020 financial results, revealing a net loss of $2.2 million, or $0.18 per share, stable compared to the previous year. R&D expenses increased slightly to $1.0 million, while G&A expenses decreased to $1.2 million. Cash reserves stood at $8.7 million, expected to fund operations through Q3 2021. The company is advancing its Phase 3 clinical development of levosimendan for pulmonary hypertension and heart failure, and an upcoming R&D webinar is set for November 18, 2020, to discuss recent trial data and updates.
Tenax Therapeutics (Nasdaq: TENX) announced data from the 24-hour open-label portion of the HELP Study, focusing on levosimendan for patients with pulmonary hypertension and heart failure. The study revealed that 36 out of 44 patients, about 85%, responded positively to a 24-hour infusion of levosimendan, showing a significant reduction in pulmonary capillary wedge pressure. These results will be presented at the AHA Scientific Sessions 2020, demonstrating support for the upcoming double-blind phase of the trial.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a virtual R&D webinar for analysts and investors on November 18, 2020, at 4:30 p.m. EST. The webinar will provide updates on levosimendan and its Phase 2 trial targeting pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Esteemed experts including Dr. Stuart Rich and Dr. Daniel Burkhoff will present findings. The trial showed significant improvements in hemodynamic measures and 6-minute walk distances. Archived recordings will be accessible on Tenax's website for 30 days.
Tenax Therapeutics (Nasdaq: TENX) has amended its licensing agreement with Orion Corporation to develop an oral formulation of levosimendan for Type 2 pulmonary hypertension in heart failure patients with preserved ejection fraction. The company plans to utilize this oral formulation in an upcoming Phase 3 trial, which is expected to accelerate patient enrollment compared to the intravenous version. The oral formulation has been previously tested in numerous patients, providing valuable data to support its use. Currently, no products are approved for treating this condition.
Tenax Therapeutics (Nasdaq: TENX) has announced the presentation of detailed results from the Phase 2 HELP Study on levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) at the upcoming HFSA Virtual Annual Meeting from September 30 to October 6. The study demonstrated significant hemodynamic improvements and enhanced exercise capacity. CEO Anthony DiTonno expressed optimism regarding the potential of levosimendan as a groundbreaking treatment, given there are currently no FDA-approved therapies for this condition.